Aim
The aim of this study was to characterize patients diagnosed with glucose transporter protein‐1 deficiency syndrome (GLUT‐1 DS) clinically and genetically, and to evaluate the effect of treatment with the classic ketogenic or modified Atkins diet.
Method
We retrospectively studied medical records of 10 patients diagnosed with GLUT‐1 DS. Four females and six males with a median age of 15 years were included.
Results
The study illustrates the genetic and clinical heterogeneity of GLUT‐1 DS. Analysis of the SLC2A1 gene disclosed a variety of mutation types. The time between onset of symptoms and diagnosis was more than 11 years on average. The outcome in those with early diagnosis and intervention was surprisingly good. All but one patient with the classic phenotype became seizure free after treatment with the classic ketogenic or modified Atkins diet. Acetazolamide was effective in one patient with paroxysmal exercise‐induced dyskinesia. A point prevalence of GLUT‐1 DS in Norway was estimated as 2.6 per 1 000 000 inhabitants.
Interpretation
Although the long‐term prognosis in patients with GLUT‐1 DS partly depends on the underlying genetics, our study supports the assumption that early initiation of treatment with a ketogenic diet may positively affect the outcome.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.